3 quick points...1) Who is this Mr. Crae constantly referenced in the letter signed by Mr. Wells and Mr. Gubitz? Why would W&G stoop this low in such an important communication? This is just not the professionalism and leadership I was expecting when being asked to "trust" and join them. Something doesn't feel quite right when this happens despite what is in their bio. Typo (x10)? Then what does that say?
2) Limited synergy? I do not believe this. Did W&G take the time to understand Bioniche's MCC platform? Is Immunocidin or, more importantly Oncocidin not compelling examples (one reality, one potential) of the link between AH (companion pet emphasis) and HH?
3) We shareholders really must be told/ learn all the facts on the potential value Bioniche's MCC platform and Urocidin by a credible third party source(s) or equivalent. I do agree with W&G that if AH is sold do we really know the potential of what Bioniche has then bet the farm on?
Another Concerned Shareholder Group please and asap....If MCC and its foreseeable by products in Urocidin, Oncocidin and Immunocidin have the true potential we have been led to believe (including the given support of Ph2 and 3a trial results for Urocidin)... I really want a 3rd concerned shareholder group to show up quickly that gets it. Finds the right structure and "leadership" to build AH (with emphasis on companion pets) along with maximizing the MCC platform in HH. Sell-off VMC and Econiche asa appropriate unless something totally unexpected (windfall-like) is heard on the conf call per the other press release received after hours.
And, have to ask again... if Urocidin is as potentially valuable as led to believe, why isn't every ounce of effort being made to solidify lucrative licensing agreements (in U.S., Europe and Japan) that negates the need to sell AH to raise cash? Time is right, particularly if Urocidin gets the green light to proceed with tests to potentially grant the NOC/c from Health Canada. And, potential Urocidin licensing partners believe funds will not be a problem as AH intended to be sold.
rg
Note: I really wish the upcoming conference call from Bioniche was regarding the outcome of their meeting with Health Canada to have transpired late this week. Surely the outcome of this meeting will provide further insight into the value (positive or less than positive) of Urocidin. Assuming we are communicated the facts.